Lorenzo Falsetti1, Giovanna Viticchi2, Laura Buratti2, Francesco Grigioni3, Alessandro Capucci4, Mauro Silvestrini2. 1. Internal and Sub-intensive Medicine Department, A.O.U. "Ospedali Riuniti", Ancona, Italy; Cardio-Nephro-Thoracic Sciences PhD School, University of Bologna, Italy. 2. Department of Experimental and Clinical Medicine, Neurological Clinic, Marche Polytechnic University, Ancona, Italy. 3. Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Italy. 4. Department of Cardiology, Clinical Cardiology, Marche Polytechnic University, Ancona, Italy.
Abstract
BACKGROUND: An association between non-valvular atrial fibrillation (NVAF) and cognitive impairment has been hypothesized. OBJECTIVE: We sought to evaluate whether and how permanent NVAF (pNVAF) is associated with progression of cognitive impairment in patients with Alzheimer's disease (AD) in the presence of vascular or genetic risk factors. METHODS: 310 consecutive patients affected by mild-moderate AD were included and followed for a 24-month period. At the end of the follow-up, based on the results of the neuropsychological evaluation patients were classified as stable or deteriorated to severe AD. Clinical history, therapy, time in therapeutic range for anticoagulation, Framingham cardiovascular risk profile (FCRP), CHA2DS2-VASc score, Mini-Mental State Examination (MMSE), ApoE genotype, brain CT-scan, carotid ultrasound, and ECG were collected. Binary logistic and path analysis were adopted to assess relationships between pNVAF, ApoE, and cognitive outcome. RESULTS: Despite anticoagulant therapy, pNVAF was associated with lower entry MMSE, higher mean intima-media thickness (mIMT) and higher FCRP. Among patients carrying ApoE ɛ4 allele and affected by pNVAF, the lowest MMSE (14.90±7.62) and the highest mIMT (1.16±0.17 mm) and FCRP (26.24±3.96) values were detected. In this group, the risk of cognitive deterioration reached the highest probability. pNVAF was associated with an increased cognitive deterioration in subjects with high FCRP, CHA2DS2-VASc, or mIMT. CONCLUSIONS: pNVAF seems to identify AD patients with a significant atherosclerotic burden and reduced cognitive performances. The interaction between pNVAF and ApoE ɛ4 genotype, especially with aggregated risk factors and an advanced stage of vascular damage is associated with higher risk of fast cognitive deterioration.
BACKGROUND: An association between non-valvular atrial fibrillation (NVAF) and cognitive impairment has been hypothesized. OBJECTIVE: We sought to evaluate whether and how permanent NVAF (pNVAF) is associated with progression of cognitive impairment in patients with Alzheimer's disease (AD) in the presence of vascular or genetic risk factors. METHODS: 310 consecutive patients affected by mild-moderate AD were included and followed for a 24-month period. At the end of the follow-up, based on the results of the neuropsychological evaluation patients were classified as stable or deteriorated to severe AD. Clinical history, therapy, time in therapeutic range for anticoagulation, Framingham cardiovascular risk profile (FCRP), CHA2DS2-VASc score, Mini-Mental State Examination (MMSE), ApoE genotype, brain CT-scan, carotid ultrasound, and ECG were collected. Binary logistic and path analysis were adopted to assess relationships between pNVAF, ApoE, and cognitive outcome. RESULTS: Despite anticoagulant therapy, pNVAF was associated with lower entry MMSE, higher mean intima-media thickness (mIMT) and higher FCRP. Among patients carrying ApoE ɛ4 allele and affected by pNVAF, the lowest MMSE (14.90±7.62) and the highest mIMT (1.16±0.17 mm) and FCRP (26.24±3.96) values were detected. In this group, the risk of cognitive deterioration reached the highest probability. pNVAF was associated with an increased cognitive deterioration in subjects with high FCRP, CHA2DS2-VASc, or mIMT. CONCLUSIONS:pNVAF seems to identify ADpatients with a significant atherosclerotic burden and reduced cognitive performances. The interaction between pNVAF and ApoE ɛ4 genotype, especially with aggregated risk factors and an advanced stage of vascular damage is associated with higher risk of fast cognitive deterioration.
Authors: Gina M Peloso; Alexa S Beiser; Claudia L Satizabal; Vanessa Xanthakis; Ramachandran S Vasan; Matthew P Pase; Anita L Destefano; Sudha Seshadri Journal: Neurology Date: 2020-07-20 Impact factor: 9.910
Authors: Michelle C Johansen; Thomas H Mosley; David S Knopman; Dean F Wong; Chiadi Ndumele; Amil M Shah; Scott D Solomon; Rebecca F Gottesman Journal: J Am Heart Assoc Date: 2020-12-08 Impact factor: 5.501
Authors: Amaryllis A Tsiknia; Emilie Reas; Katherine J Bangen; Erin E Sundermann; Linda McEvoy; James B Brewer; Steven D Edland; Sarah J Banks Journal: Brain Commun Date: 2022-02-18
Authors: Rayan Anbar; Salahaden R Sultan; Lamia Al Saikhan; Mohammed Alkharaiji; Nishi Chaturvedi; Rebecca Hardy; Marcus Richards; Alun Hughes Journal: BMJ Open Date: 2022-04-19 Impact factor: 3.006
Authors: Tamas Fulop; Jacek M Witkowski; Karine Bourgade; Abdelouahed Khalil; Echarki Zerif; Anis Larbi; Katsuiku Hirokawa; Graham Pawelec; Christian Bocti; Guy Lacombe; Gilles Dupuis; Eric H Frost Journal: Front Aging Neurosci Date: 2018-07-24 Impact factor: 5.750